


Claims

1. The use of compounds of the general formula (I)



5

in which

- R¹ is -C₁-C₆-alkyl, straight-chain or branched-chain, saturated or partially unsaturated, where appropriate substituted one or more times by mono-, bi- or
- 10 tricyclic saturated or mono- or polyunsaturated carbocycles having 3-14 ring members or mono-, bi- or tricyclic saturated or mono- or polyunsaturated heterocycles having 5-15 ring members and 1-6 heteroatoms, which are preferably N, O and S,
- 15 where the carbocyclic and heterocyclic substituents in turn may be substituted where appropriate one or more times by -OH, -SH, -NH₂, -NHC₁-C₆-alkyl, -N(C₁-C₆-alkyl)₂, -NHC₆-C₁₄-aryl, -N(C₆-C₁₄-aryl)₂, -N(C₁-C₆-alkyl)(C₆-C₁₄-aryl), -NO₂, -CN, -F, -Cl, -Br, -I,
- 20 -O-C₁-C₆-alkyl, -O-C₆-C₁₄-aryl, -C₁-C₆-alkyl, -C₆-C₁₄-aryl or/and -COOH,
- where each C₁-C₆-alkyl radical on the carbocyclic and heterocyclic substituents may itself be substituted one or more times by -F, -Cl, -Br, -I, -OH or/and C₆-C₁₄-
- 25 aryl, and where each C₆-C₁₄-aryl radical on the carbocyclic and heterocyclic substituents may itself be substituted one or more times by -F, -Cl, -Br, -I, -OH or/and C₁-C₆-alkyl,

- 30 R², R³ may be hydrogen or -OH, it being necessary for at least one of the two substituents to be -OH;

- R^4 is a mono- or polycyclic aromatic carbocycle having 6-14 ring members or a mono- or polycyclic heterocycle having 5-15 ring members, where the heteroatoms are selected from N, O and S,
- 5 where appropriate substituted one or more times by -F, -Cl, -Br, -I, -OH, -SH, -NH₂, -NH(C₁-C₆-alkyl), -N(C₁-C₆-alkyl)₂, -NH(C₆-C₁₄-aryl), -N(C₆-C₁₄-aryl)₂, -N(C₁-C₆-alkyl)(C₆-C₁₄-aryl), -NO₂, -CN, -O-C₁-C₆-alkyl, -O-C₆-C₁₄-aryl, -C₁-C₆-alkyl, -C₆-C₁₄-aryl or/and -COOH,
- 10 where each C₁-C₆-alkyl radical may itself be substituted one or more times by -F, -Cl, -Br, -I, -OH or/and -C₆-C₁₄-aryl and each C₆-C₁₄-aryl radical may itself be substituted one or more times by -F, -Cl, -Br, -I, -OH or/and C₁-C₆-alkyl,
- 15 for the treatment of nonallergic rhinitis.

2. The use as claimed in claim 1, **characterized in that**
- 20 the compounds are N-(3,5-dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxyindol-3-yl]glyoxylamide (AWD 12-281), N-(3,5-dichloropyrid-4-yl)-2-[5-hydroxy-1-(4-hydroxybenzyl)-1H-indol-3-yl]glyoxylamide (AWD 12-322) and N-(3,5-dichloropyrid-4-yl)-[1-(2,6-difluorobenzyl)-5-hydroxyindol-3-yl]glyoxylamide semi-ethyl acetate
- 25 (AWD 12-298) or the pharmacologically acceptable salts thereof.

3. The use as claimed in claim 1 or 2, **characterized in that**
- 30 the nonallergic rhinitis is selected from vasomotor rhinitis, nonallergic rhinitis with eosinophils syndrome, chronic sinusitis and rhinitis medicamentosa.

4. The use as claimed in claim 1 or 2, **characterized in that**
- 35 the rhinitis caused by infection is a symptom, not caused by allergy, of a viral or bacterial infection or of an infection with fungi or parasites or of a combination of the germs mentioned, selected from

vasomotor rhinitis, nonallergic rhinitis with
eosinophils syndrome, chronic sinusitis and rhinitis
medicamentosa.